BACKGROUND: Ranolazine is a new anti-anginal agent that inhibits abnormal late sodium currents, indirectly causing a decrease in diastolic cardiomyocyte calcium levels. This produces an energy-sparing effect and stabilizes cardiac membranes. Ranolazine has been shown to be a potent inhibitor of triggered activity in the experimental setting. METHODS: This case report describes the dramatic antiarrhythmic effects of ranolazine in a patient with highly symptomatic complex ventricular ectopy, including non-sustained ventricular tachycardia (NSVT). Cardiac ischemia and left ventricular systolic dysfunction were ruled out by cardiac catheterization. After failing standard treatment, we initiated ranolazine therapy. RESULTS: Ranolazine was effective in suppressing ectopic ventricular activity and completely suppressed NSVT. CONCLUSIONS: Further research on the anti-arrhythmic properties of ranolazine in the clinical setting is needed.
BACKGROUND:Ranolazine is a new anti-anginal agent that inhibits abnormal late sodium currents, indirectly causing a decrease in diastolic cardiomyocyte calcium levels. This produces an energy-sparing effect and stabilizes cardiac membranes. Ranolazine has been shown to be a potent inhibitor of triggered activity in the experimental setting. METHODS: This case report describes the dramatic antiarrhythmic effects of ranolazine in a patient with highly symptomatic complex ventricular ectopy, including non-sustained ventricular tachycardia (NSVT). Cardiac ischemia and left ventricular systolic dysfunction were ruled out by cardiac catheterization. After failing standard treatment, we initiated ranolazine therapy. RESULTS:Ranolazine was effective in suppressing ectopic ventricular activity and completely suppressed NSVT. CONCLUSIONS: Further research on the anti-arrhythmic properties of ranolazine in the clinical setting is needed.
Authors: Andrew C Zygmunt; Vladislav V Nesterenko; Sridharan Rajamani; Dan Hu; Hector Barajas-Martinez; Luiz Belardinelli; Charles Antzelevitch Journal: Am J Physiol Heart Circ Physiol Date: 2011-08-05 Impact factor: 4.733
Authors: Eric Yeung; Mori J Krantz; Joseph L Schuller; Rita A Dale; Mark C Haigney Journal: Ann Noninvasive Electrocardiol Date: 2014-02-17 Impact factor: 1.468